SCHEMBL831390

SCHEMBL831390

Cc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C1CC1)n2Cc1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.39
AURKA O14965 1/20 0.34
TPX2 Q9ULW0 1/20 0.34
SCN9A Q15858 4/20 0.33
SCN5A Q14524 3/20 0.33
SCN2B O60939 2/20 0.33
SCN1B Q07699 2/20 0.33
KMT2A Q03164 2/20 0.33
SCN1A P35498 1/20 0.33
MOGAT2 Q3SYC2 3/20 0.32
CYP2C9 P11712 2/20 0.32
MGAT2 Q10469 1/20 0.32
MAPT P10636 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
CDK2 P24941 1/20 0.31
LMNA P02545 2/20 0.31
PARG Q86W56 1/20 0.30
PTGDR2 Q9Y5Y4 2/20 0.30
MEN1 O00255 1/20 0.30
SLC5A1 P13866 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13905361 0.94 CYP2C8 (0.38) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831548 0.93 NOX4 (0.37) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL10256456 0.93 CYP2C8 (0.42) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL832004 0.92 CYP2C8 (0.38) CYP2C8AURKATPX2KMT2AMAPT
SCHEMBL831480 0.92 CYP2C8 (0.39) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL832072 0.92 CYP2C8 (0.36) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831673 0.92 CYP2C8 (0.48) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL833251 0.91 CYP2C8 (0.36) CYP2C8AURKATPX2SCN9ASCN5A
SCHEMBL831753 0.91 CYP2C8 (0.41) CYP2C8SCN9AKMT2AMAPTSMN1; SMN2
SCHEMBL831741 0.91 CYP2C8 (0.41) CYP2C8AURKATPX2SCN9ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885AURKA 1855/4885TPX2 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.